- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01098110
6-week Trial of the Efficacy and Safety of Asenapine Compared to Placebo in Participants With an Acute Exacerbation of Schizophrenia (P06124)
February 3, 2022 updated by: Organon and Co
A Multicenter, Randomized, Double-blind, Fixed-dose, 6-week Trial of the Efficacy and Safety of Asenapine Compared With Placebo in Subjects With an Acute Exacerbation of Schizophrenia (Phase 3)
A multicenter, randomized, parallel-group, double-blind, fixed dose, 6-week trial of the efficacy and safety of asenapine compared with placebo in participants with an acute exacerbation of schizophrenia.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
532
Phase
- Phase 3
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
20 years to 64 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- current diagnosis of schizophrenia of paranoid, disorganized, catatonic, or undifferentiated (295.90) subtype
- minimum Positive and Negative Syndrome Scale (PANSS) total score of 60 at screening and Baseline.
- participant had a score of at least 4 in two or more of 5 items in the positive subscale of the PANSS at Screening and Baseline.
participant confirmed by the investigator to be experiencing an acute exacerbation of schizophrenia as evidenced by ALL of the following:
- at the screening test, the duration of the current episode was no more than 2 months;
- current symptoms represented a dramatic and substantial change compared to the participant's symptomatic state prior to the emergence of the current episode;
- participant was in need of changing medication or dosage to treat newly appeared or worsened positive symptoms.
- participant had a Clinical Global Impressions-Severity (CGI-S) scale score of at least 4 (moderately ill) at Baseline;
- responded positively to an antipsychotic medication in a prior episode.
- discontinued the use of all prohibited concomitant medications, with last dose taken no later than the evening prior to the baseline visit (For depot neuroleptic, discontinuation must have occurred more than 3 months prior to randomization).
- participants must agree to inpatient status for screening period and for up to 42 days of dosing and, for out-patient phase, had a caregiver or an identified responsible person (e.g., family member, social worker, case worker, or nurse) whom the investigator accepts and who has agreed to provide support to the participant to ensure compliance with study treatment, out-patient visits, and protocol procedures.
Exclusion Criteria:
- not be treatment-refractory defined by the following criteria: (1) had been treated with at least two different atypical anti-psychotic agents at dosages equivalent to or greater than 600 mg/day of chlorpromazine (12 mg /day of haloperidol) for more than 4 weeks, each without clinical response, or (2) has received clozapine for 12 weeks immediately preceding the screening.
- not have received treatment with 3 or more antipsychotic drugs, or dose-equivalents higher than 18 mg/day of haloperidol (equivalent 900 mg/day of chlorpromazine) within one month prior to randomization.
- not have a diagnosis of schizoaffective disorder; schizophrenia of residual subtype; schizophreniform disorder, or schizophrenia with course specifiers continuous, single episode in partial remission, or single episode in full remission
- not have a concurrent psychiatric disorder other than schizophrenia coded on Axis I; not have a primary diagnosis other than schizophrenia
- not have had a known diagnosis of borderline personality disorder, mental retardation or organic brain disorder.
- not have a 20% or greater decrease in PANSS total score from screening to baseline
- not have an imminent risk of self-harm or harm to others, in the investigator's opinion.
- not have a substance induced psychotic disorder or a behavioral disturbance thought to be due to substance abuse
- not be currently under involuntary in-patient confinement.
- not been previously treated with asenapine.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Asenapine 5 mg BID
Participants received a 5 mg asenapine fast dissolving tablet twice daily (BID) for 6 weeks.
|
Asenapine 5 mg fast dissolving tablets sublingually without water twice daily, in the morning (around 8 am) and in the evening (around 8 pm), on Day 1 only or for 6 weeks.
Other Names:
|
Experimental: Asenapine 10 mg BID
Participants received a 5 mg asenapine fast dissolving tablet BID on Day 1, then 10 mg asenapine fast dissolving tablet BID thereafter for a total of 6 weeks.
|
Asenapine 5 mg fast dissolving tablets sublingually without water twice daily, in the morning (around 8 am) and in the evening (around 8 pm), on Day 1 only or for 6 weeks.
Other Names:
Participants receive on Day 2, 10 mg BID of fast dissolving tablets sublingually without water twice daily, in the morning (around 8 am) and in the evening (around 8 pm), for 6 weeks.
Other Names:
|
Placebo Comparator: Placebo BID
Participants received matching placebo BID for 6 weeks.
|
A matching placebo of asenapine sublingual tablet not containing asenapine
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score.
Time Frame: Baseline and Day 42
|
PANSS total score measures symptoms of schizophrenia and consists of responses to 30 items: 7 items from the positive subscale (P1-P7), 7 items from the negative subscale (N1-N7) and 16 items from the general psychopathology subscale (G1-G16).
Responses to each item range from 1 = absence of symptom, to 7 = most extreme symptoms.
The PANSS total score is the sum of the scores for all 30 items, and ranges from 30 to 210, with a higher score indicating greater severity of symptoms.
Change from baseline values that are negative represent an improvement in symptoms.
|
Baseline and Day 42
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change From Baseline in PANSS Positive Symptom Score.
Time Frame: Baseline and Day 42
|
PANSS Positive subscale measures symptoms of schizophrenia and consists of responses to 7 items (P1-P7).
Responses to each item range from 1 = absence of symptom, to 7 = most extreme symptoms.
The PANSS Positive subscale sums all 7 items and ranges from 7 to 49, with a higher score indicating greater severity of symptoms.
An improvement in symptoms is represented by change from baseline values that are negative.
|
Baseline and Day 42
|
Change From Baseline in PANSS Negative Symptom Score.
Time Frame: Baseline and Day 42
|
PANSS Negative subscale measures symptoms of schizophrenia and consists of responses to 7 items (N1-N7).
Responses to each item range from 1 = absence of symptom, to 7 = most extreme symptoms.
The PANSS Negative subscale sums all 7 items and ranges from 7 to 49, with a higher score indicating greater severity of symptoms. .
An improvement in symptoms is represented by change from baseline values that are negative.
|
Baseline and Day 42
|
Change From Baseline in PANSS General Psychopathology Score.
Time Frame: Baseline and Day 42
|
PANSS General Psychopathology subscale measures symptoms of schizophrenia and consists of responses to 16 items (G1-G16).
Responses to each item range from 1 = absence of symptom, to 7 = most extreme symptoms.
The PANSS General Psychopathology subscale is the sum of the scores for all 16 items and ranges from 16 to 112, with a higher score indicating greater severity of symptoms..
An improvement in symptoms is represented by change from baseline values that are negative.
|
Baseline and Day 42
|
Change From Baseline in PANSS Marder Factor Positive Symptom Score.
Time Frame: Baseline and Day 42
|
PANSS Marder Factor Positive symptom score measures symptoms of schizophrenia and consists of responses to 8 items (P1,P3,P5,P6,N7,G1,G9,G12).
Responses to each item range from 1 = absence of symptom, to 7 = most extreme symptoms.
The PANSS Marder Factor Positive symptom score is the sum of the scores for all 8 items and ranges from 8 to 56, with a higher score indicating greater severity of symptoms.
An improvement in symptoms is represented by change from baseline values that are negative.
|
Baseline and Day 42
|
Change From Baseline in PANSS Marder Factor Negative Symptom Score.
Time Frame: Baseline and Day 42
|
PANSS Marder Factor Negative symptom score measures symptoms of schizophrenia and consists of responses to 7 items (N1,N2,N3,N4,N6,G7,G16). Responses to each item range from 1 = absence of symptom, to 7 = most extreme symptoms.
The PANSS Marder Factor Negative symptom score is the sum of the scores for all 7 items and ranges from 7 to 49, with a higher score indicating greater severity of symptoms.
An improvement in symptoms is represented by change from baseline values that are negative.
|
Baseline and Day 42
|
Change From Baseline in PANSS Marder Factor Disorganized Thought Symptom Score.
Time Frame: Baseline and Day 42
|
PANSS Marder Factor Disorganized Thought symptom score measures symptoms of schizophrenia and consists of responses to 7 items (P2,N5,G5,G10,G11,G13,G15).
Responses to each item range from 1 = absence of symptom, to 7 = most extreme symptoms.
The PANSS Marder Factor Disorganized Thought symptom score is the sum of the scores for all 7 items and ranges from 7 to 49, with a higher score indicating greater severity of symptoms.
An improvement in symptoms is represented by change from baseline values that are negative.
|
Baseline and Day 42
|
Change From Baseline in PANSS Marder Factor Hostility/Excitement Symptom Score.
Time Frame: Baseline and Day 42
|
PANSS Marder Factor Hostility/Excitement symptom score measures symptoms of schizophrenia and consists of responses to 4 items (P4,P7,G8,G14).
Responses to each item range from 1 = absence of symptom, to 7 = most extreme symptoms.
The PANSS Marder Factor Hostility/Excitement symptom score is the sum of the scores for all 4 items and ranges from 4 to 28, with a higher score indicating greater severity of symptoms.
An improvement in symptoms is represented by change from baseline values that are negative.
|
Baseline and Day 42
|
Change From Baseline in PANSS Marder Factor Anxiety/Depression Symptom Score.
Time Frame: Baseline and Day 42
|
PANSS Marder Factor Anxiety/Depression symptom score measures symptoms of schizophrenia and consists of responses to 4 items (G2,G3,G4,G6).
Responses to each item range from 1 = absence of symptom, to 7 = most extreme symptoms.
The PANSS Marder Factor Anxiety/Depression symptom score is the sum of the scores for all 4 items and ranges from 4 to 28, with a higher score indicating greater severity of symptoms.
An improvement in symptoms is represented by change from baseline values that are negative.
|
Baseline and Day 42
|
Percentage of Participants Who Were PANSS Responders.
Time Frame: Day 42
|
PANSS total score measures symptoms of schizophrenia and consists of responses to 30 items: 7 items from the positive subscale (P1-P7), 7 items from the negative subscale (N1-N7) and 16 items from the general psychopathology subscale (G1-G16).
Responses to each item range from 1 = absence of symptom, to 7 = most extreme symptoms.
The PANSS total score is the sum of the scores for all 30 items, and ranges from 30 to 210, with a higher score indicating greater severity of symptoms.
The PANSS total score was determined at baseline and then at Day 42, and a participant with a 30% or greater reduction from baseline in PANSS total score at Day 42 was considered a PANSS responder.
|
Day 42
|
Change From Baseline in Clinical Global Impressions -Severity of Illness (CGI-S) Score.
Time Frame: Baseline and Day 42
|
The CGI-S is a score that measures the severity of overall bipolar illness.
The score ranges on a scale from 1 to 7, where 1 is normal, and 7 is very severely ill.
Change from baseline values that are negative represent an improvement in symptoms.
|
Baseline and Day 42
|
Percentage of Participants Who Were Clinical Global Impressions - Improvement (CGI-I) Responders.
Time Frame: Day 42
|
The CGI-I is a score on a 7-point scale for assessing the change from preceding phase of overall symptoms of bipolar disorder during the treatment of an acute episode or in longer term illness prophylaxis.
Compared to the baseline, the CGI-I score ranges from 1 = very much improved since initiating treatment, to 7 = very much worse since initiating treatment.
The CGI-I score was assessed at baseline and Day 42.
Compared to the baseline measurement, a CGI-I responder had a score at Day 42 of 3 (minimally improved), 2 (much improved) or 1 (very much improved).
|
Day 42
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
May 25, 2010
Primary Completion (Actual)
April 14, 2014
Study Completion (Actual)
April 14, 2014
Study Registration Dates
First Submitted
April 1, 2010
First Submitted That Met QC Criteria
April 1, 2010
First Posted (Estimate)
April 2, 2010
Study Record Updates
Last Update Posted (Actual)
February 7, 2022
Last Update Submitted That Met QC Criteria
February 3, 2022
Last Verified
February 1, 2022
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- P06124
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
YES
IPD Plan Description
https://www.merck.com/clinical-trials/pdf/ProcedureAccessClinicalTrialData.pdf
Study Data/Documents
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Schizophrenia
-
Organon and CoCompletedSchizophrenia, Paranoid | Schizophrenia, Disorganized | Schizophrenia, Undifferentiated
-
Organon and CoCompletedSchizophrenia, Paranoid | Schizophrenia, Disorganized | Schizophrenia, Undifferentiated
-
Bradley LegaRecruiting
-
All India Institute of Medical Sciences, BhubaneswarRecruitingTreatment Resistant SchizophreniaIndia
-
King's College LondonSouth London and Maudsley NHS Foundation TrustRecruitingTreatment-resistant Schizophrenia | Healthy Controls | Treatment-responsive SchizophreniaUnited Kingdom
-
University of Sao PauloUnknownRefractory Schizophrenia | Super Refractory SchizophreniaBrazil
-
Peking UniversityNot yet recruitingTreatment-resistant Schizophrenia
-
Ohio State UniversityRecruitingTreatment-resistant SchizophreniaUnited States
-
University Hospital, BrestRecruitingSchizophrenia | Schizophrenia Prodromal | Schizophrenia, ChildhoodFrance
-
NYU Langone HealthNot yet recruitingTreatment-resistant SchizophreniaUnited States
Clinical Trials on Asenapine 5 mg
-
Organon and CoCompleted
-
Duke UniversityMerck Sharp & Dohme LLCCompleted
-
Duke UniversityMerck Sharp & Dohme LLCCompletedMajor Depressive Disorder Without Psychotic FeaturesUnited States
-
Organon and CoCompletedSchizophrenia, Paranoid | Schizophrenia, Disorganized | Schizophrenia, Undifferentiated
-
Amneal Pharmaceuticals, LLCAccutest Research Laboratories (I) Pvt. Ltd.Completed
-
Lori Davis, MDMerck Sharp & Dohme LLC; Forest LaboratoriesCompletedAn Open Label Pilot Study of Adjunctive Asenapine for the Treatment of Posttraumatic Stress DisorderPosttraumatic Stress DisorderUnited States
-
PfizerCompleted
-
Organon and CoCompleted
-
Anesiva, Inc.CompletedTotal Knee Arthroplasty (Replacement)United States